Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants
Abstract Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a 5‐year survival rate of less than 10%. Individuals with a pathogenic germline variant in a pancreatic cancer susceptibility gene are at an increased risk of developing pancreatic cancer. Understanding the inherited genetic basis of pancreatic tumor development provides a unique opportunity to improve patient care and outcomes. For example, relatives of a patients with PDAC who have a pathogenic germline variant in a pancreatic cancer susceptibility gene are eligible for disease surveillance where cancers may be detected early, and 5‐year survival greatly improved. Furthermore, for some patients with PDAC and a pathogenic germline variant in a pancreatic cancer susceptibility gene, their tumors may be susceptible to specific anti‐cancer therapies. Recently, RABL3 was identified as a pancreatic cancer susceptibility gene. To validate these findings and inform clinical translation, we determined the prevalence of deleterious RABL3 variants in a large cohort of 1037 patients with PDAC that had undergone either whole genome or whole exome germline sequencing. We identified two synonymous variants and four missense variants classified as variants of unknown significance. We found no pathogenic RABL3 variants, indicating that the maximum prevalence of such variants in patients with PDAC is less than 0.36% (minor allele frequency 0, 97.5% one‐sided confidence interval: 0‐0.0036). This finding has important implications for germline genetic testing of patients with PDAC..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:60 |
|---|---|
| Enthalten in: |
Genes, Chromosomes and Cancer - 60(2021), 8, Seite 559-564 |
| Beteiligte Personen: |
Roberts, Nicholas J. [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2021 Wiley Periodicals LLC. |
|---|
| Umfang: |
6 |
|---|
| doi: |
10.1002/gcc.22947 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY006671357 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY006671357 | ||
| 003 | DE-627 | ||
| 005 | 20230307162824.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2021 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/gcc.22947 |2 doi | |
| 028 | 5 | 2 | |a GCC_GCC22947.xml |
| 035 | |a (DE-627)WLY006671357 | ||
| 035 | |a (WILEY)GCC22947 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 570 |a 610 |q ASE |
| 084 | |a 42.20 |2 bkl | ||
| 084 | |a 44.48 |2 bkl | ||
| 084 | |a 44.81 |2 bkl | ||
| 100 | 1 | |a Roberts, Nicholas J. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants |
| 264 | 1 | |c 2021 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2021 Wiley Periodicals LLC. | ||
| 520 | |a Abstract Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with a 5‐year survival rate of less than 10%. Individuals with a pathogenic germline variant in a pancreatic cancer susceptibility gene are at an increased risk of developing pancreatic cancer. Understanding the inherited genetic basis of pancreatic tumor development provides a unique opportunity to improve patient care and outcomes. For example, relatives of a patients with PDAC who have a pathogenic germline variant in a pancreatic cancer susceptibility gene are eligible for disease surveillance where cancers may be detected early, and 5‐year survival greatly improved. Furthermore, for some patients with PDAC and a pathogenic germline variant in a pancreatic cancer susceptibility gene, their tumors may be susceptible to specific anti‐cancer therapies. Recently, RABL3 was identified as a pancreatic cancer susceptibility gene. To validate these findings and inform clinical translation, we determined the prevalence of deleterious RABL3 variants in a large cohort of 1037 patients with PDAC that had undergone either whole genome or whole exome germline sequencing. We identified two synonymous variants and four missense variants classified as variants of unknown significance. We found no pathogenic RABL3 variants, indicating that the maximum prevalence of such variants in patients with PDAC is less than 0.36% (minor allele frequency 0, 97.5% one‐sided confidence interval: 0‐0.0036). This finding has important implications for germline genetic testing of patients with PDAC. | ||
| 700 | 1 | |a Grant, Robert C. |4 aut | |
| 700 | 1 | |a Gallinger, Steven |4 aut | |
| 700 | 1 | |a Klein, Alison P. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Genes, Chromosomes and Cancer |g 60(2021), 8, Seite 559-564 |w (DE-627)WLY006669026 |x 10982264 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:2021 |g number:8 |g pages:559-564 |g extent:6 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 42.20 |q ASE |
| 936 | b | k | |a 44.48 |q ASE |
| 936 | b | k | |a 44.81 |q ASE |
| 951 | |a AR | ||
| 952 | |d 60 |j 2021 |e 8 |h 559-564 |g 6 | ||